Literature DB >> 3299179

A comparison of nonculture-dependent methods for detection of Chlamydia trachomatis infections in pregnant women.

V S Baselski, S G McNeeley, G Ryan, M Robison.   

Abstract

Two nonculture-dependent methods for the detection of Chlamydia trachomatis in endocervical samples from obstetric patients were compared with routine isolation in McCoy cell cultures. When compared with culture, the sensitivities and specificities of the methods were: direct fluorescent antibody staining (MicroTrak [Syva Co.]) 98.1 and 95.4%, and enzyme immunoassay (Chlamydiazyme [Abbott Laboratories]) 96.3 and 92.9%, respectively. In 89% of apparent false-positive direct fluorescent antibody cases and 64% of enzyme immunoassay cases, an additional positive nonculture result was considered to indicate infection missed by culture. Considering these data, revised sensitivities were 84.4% for culture, 95.2% for direct fluorescent antibody, and 95.3% for enzyme immunoassay. Revised specificities were 99.5% for direct fluorescent antibody and 97.3% for enzyme immunoassay. Both nonculture tests appear acceptable for screening high-risk obstetric patients, and may be more sensitive than routine cell culture.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3299179

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  16 in total

1.  Ortho enzyme immunoassay versus McCoy cell monolayers stained by iodine or fluorescent antibody for detection of Chlamydia trachomatis.

Authors:  L E Phillips; P B Smith; G D Riddle; S Faro; H K Goodrich; M G Martens
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

2.  Accuracy of Chlamydia trachomatis antigen detection methods in a low-prevalence population in a primary care setting.

Authors:  P H Gann; J E Herrmann; L Candib; R W Hudson
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

3.  Endocervical Chlamydia trachomatis infection in Canadian adolescents.

Authors:  E G Hughes; J Mowatt; J E Spence
Journal:  CMAJ       Date:  1989-02-01       Impact factor: 8.262

4.  Cervico-vaginal Chlamydia trachomatis infection in pregnant adolescent and adult women. A morphologic and immunofluorescent study.

Authors:  M J Cavaliere; M Y Maeda; N K Shirata; A Longatto Filho; L W Shih; M de Siqueira; M G de Muelenare Correa; H F Oliveira
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

5.  Confirmation of positive results for chlamydial antigen by the Chlamydiazyme assay: value of repeated testing and a blocking antibody assay.

Authors:  M A Olsen; A R Sambol
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

6.  Evaluation of a nonisotopic probe for detection of Chlamydia trachomatis in endocervical specimens.

Authors:  G L Woods; A Young; J C Scott; T M Blair; A M Johnson
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

7.  Comparison of the Syva MicroTrak enzyme immunoassay and Gen-Probe PACE 2 with cell culture for diagnosis of cervical Chlamydia trachomatis infection in a high-prevalence female population.

Authors:  L M Clarke; M F Sierra; B J Daidone; N Lopez; J M Covino; W M McCormack
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

8.  Prevalence of Chlamydia trachomatis infection in pregnant patients.

Authors:  D H Much; S Y Yeh
Journal:  Public Health Rep       Date:  1991 Sep-Oct       Impact factor: 2.792

9.  Efficacy of duplicate genital specimens and repeated testing for confirming positive results for chlamydiazyme detection of Chlamydia trachomatis antigen.

Authors:  J A Kellogg; J W Seiple; J S Levisky
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

10.  Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women.

Authors:  L M Baddour; R S Gibbs; G Mertz; D M Cocchetto; R C Noble
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.